- Report
- January 2025
- 182 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- December 2024
- 200 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Report
- May 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- May 2024
- 90 Pages
United States
From €3770EUR$3,950USD£3,159GBP
- Report
- July 2022
- 263 Pages
Global
From €1800EUR$2,020USD£1,561GBP
- Report
- December 2022
- 363 Pages
Global
From €4580EUR$4,799USD£3,837GBP
- Report
- September 2022
- 799 Pages
Global
From €4580EUR$4,799USD£3,837GBP
- Report
- March 2021
- 397 Pages
Global
From €4580EUR$4,799USD£3,837GBP
- Report
- May 2023
- 391 Pages
Global
From €4580EUR$4,799USD£3,837GBP
- Report
- April 2019
- 850 Pages
Global
From €4294EUR$4,499USD£3,598GBP
- Report
- May 2022
- 50 Pages
Global
From €500EUR$561USD£434GBP
- Report
- August 2023
- 267 Pages
Global
From €2150EUR$2,413USD£1,864GBP
- Report
- June 2022
- 115 Pages
Global
From €1050EUR$1,179USD£911GBP
- Report
- May 2022
- 32 Pages
Global
From €400EUR$449USD£347GBP
- Report
- March 2025
Global
From €400EUR$449USD£347GBP
- Report
- March 2025
Global
From €300EUR$337USD£260GBP
- Report
- December 2023
- 220 Pages
Global
From €3149EUR$3,300USD£2,639GBP
- Report
- October 2023
- 420 Pages
Global
From €2768EUR$2,900USD£2,319GBP
- Drug Pipelines
- August 2023
- 400 Pages
China
From €2863EUR$3,000USD£2,399GBP
- Drug Pipelines
- August 2023
- 580 Pages
United States
From €4008EUR$4,200USD£3,358GBP

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases.
Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments.
The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more